everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...1011121314151617181920...132133»
  • ||||||||||  Review, Journal:  A review of heart transplant immunosuppressants and nonmelanoma skin cancer. (Pubmed Central) -  May 31, 2023   
    A management strategy in immunosuppression-associated skin cancers may ultimately involve adjusting the immunosuppressive regimen. This review serves as a summary of the most commonly used immunosuppressive drugs in heart transplant patients and their tumorigenic mechanisms to guide recommendations for dermatologic follow-up in heart transplant recipients.
  • ||||||||||  everolimus / Generic mfg.
    Review, Journal, Post-transplantation:  mTOR-inhibitors and post-transplant diabetes mellitus: a link still debated in kidney transplantation. (Pubmed Central) -  May 30, 2023   
    The mammalian target of rapamycin inhibitors (mTOR-Is, Sirolimus, and Everolimus) are immunosuppressive drugs widely employed in kidney transplantation...In our opinion, based on the published reports, we cannot draw any conclusion and PTDM remains a challenge. However, also in this case, the administration of the lowest possible dose of mTOR-I should also be recommended.
  • ||||||||||  Trial completion date, Trial primary completion date:  ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (clinicaltrials.gov) -  May 30, 2023   
    P1/2,  N=460, Recruiting, 
    In the future, the method used in this study will be applied to the development of new antipsychotic drugs, including drug repositioning, and to the discovery of the pathophysiology of schizophrenia. Trial completion date: Jan 2022 --> Aug 2027 | Trial primary completion date: Jan 2022 --> Aug 2027
  • ||||||||||  sirolimus / Generic mfg.
    The impact of early sirolimus treatment on the tuberous sclerosis complex clinical outcome - a case report (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_868;    
    Despite of the factors predictive for severe clinical manifestations of TSC (TSC2 mutation, polycystic kidney changes), the successful control of cardiological and neurological TSC-manifestations was obtained in the reported case. Initiation of sirolimus therapy in infancy might have positive impact on the clinical outcome, thus additional studies are needed to establish the optimal treatment of newborns with TSC.
  • ||||||||||  sirolimus / Generic mfg.
    Review, Journal:  Three Layers of Personalized Medicine in the Use of Sirolimus and Its Derivatives for the Treatment of Cancer. (Pubmed Central) -  May 27, 2023   
    Current evidence suggests that tumors with mutations in the mTOR signal transduction pathway are sensitive to rapalogue treatment; the rapalogues are metabolized by cytochromes such as CYP3A4, CYP3A5, and CYP2C8 and transported by ABC transporters that are known to vary in activity in individuals; and that tumors can express these transporters and detoxifying enzymes. This results in three levels of genetic analysis that could impact the effectiveness of the mTOR inhibitors.
  • ||||||||||  cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
    Journal:  Prenatal Exposition to Different Immunosuppressive Protocols Results in Vacuolar Degeneration of Hepatocytes. (Pubmed Central) -  May 27, 2023   
    Area, perimeter, axis length, eccentricity and circularity regarding vacuolar degeneration were analysed. The most prominent vacuolar degeneration in hepatocytes in the aspects of presence, area and perimeter was observed in rats exposed to tacrolimus, mycophenolate mofetil and glucocorticoids, and cyclosporine A, everolimus with glucocorticoids.This is the first study that demonstrates the results of the influence of multidrug immnunosuppression distributed in utero on the hepatic tissue of offspring.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative (clinicaltrials.gov) -  May 26, 2023   
    P2,  N=17, Completed, 
    The most prominent vacuolar degeneration in hepatocytes in the aspects of presence, area and perimeter was observed in rats exposed to tacrolimus, mycophenolate mofetil and glucocorticoids, and cyclosporine A, everolimus with glucocorticoids.This is the first study that demonstrates the results of the influence of multidrug immnunosuppression distributed in utero on the hepatic tissue of offspring. Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Trial completion:  CEVOREM: Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas (clinicaltrials.gov) -  May 25, 2023   
    P2,  N=20, Completed, 
    Pembrolizumab remains the only modern therapy available in the adjuvant setting, and the waters surrounding cytoreductive nephrectomy are still murky. Unknown status --> Completed
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial primary completion date, Combination therapy, Metastases:  Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors (clinicaltrials.gov) -  May 23, 2023   
    P2,  N=32, Recruiting, 
    N=104 --> 4 | Recruiting --> Terminated; Study was larger than expected and became a burden to faculty and staff resources. Trial primary completion date: Jun 2023 --> Jun 2024
  • ||||||||||  everolimus / Generic mfg.
    Enrollment change, Trial termination, Monotherapy:  Everolimus Monotherapy as Immunosuppression After Liver Transplant (clinicaltrials.gov) -  May 23, 2023   
    P3,  N=14, Terminated, 
    Trial primary completion date: Jun 2023 --> Jun 2024 N=104 --> 14 | Recruiting --> Terminated; Study was larger than expected and became a burden to faculty and staff resources.
  • ||||||||||  Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov) -  May 22, 2023   
    P1,  N=2, Active, not recruiting, 
    N=104 --> 14 | Recruiting --> Terminated; Study was larger than expected and became a burden to faculty and staff resources. Recruiting --> Active, not recruiting | N=40 --> 2 | Trial completion date: Feb 2026 --> Jun 2027 | Trial primary completion date: Feb 2023 --> Jun 2025
  • ||||||||||  Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap
    Journal:  Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration. (Pubmed Central) -  May 20, 2023   
    Diuretics are the mainstay of heart failure symptom management for patients who develop CaHD. Considerations for future research are discussed, including the ongoing TELEHEART (TELotristat Ethyl in a HEART biomarker study) trial involving telotristat and not yet activated CHARRT (Carcinoid Heart disease And peptide Receptor Radiotargetted Therapy) study involving PRRT with lutetium 177 (177Lu) dotatate.
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date, Metastases:  Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) -  May 16, 2023   
    P1,  N=20, Recruiting, 
    Considerations for future research are discussed, including the ongoing TELEHEART (TELotristat Ethyl in a HEART biomarker study) trial involving telotristat and not yet activated CHARRT (Carcinoid Heart disease And peptide Receptor Radiotargetted Therapy) study involving PRRT with lutetium 177 (177Lu) dotatate. Not yet recruiting --> Recruiting | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024
  • ||||||||||  Enrollment closed, Trial primary completion date, Metastases:  FUTURE-SUPER: An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (clinicaltrials.gov) -  May 16, 2023   
    P2,  N=139, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2022 --> Nov 2023
  • ||||||||||  everolimus / Generic mfg.
    Review, Journal, BRCA Biomarker, IO biomarker:  Evaluating everolimus for the treatment of breast cancer. (Pubmed Central) -  May 15, 2023   
    Because of its efficacy, acceptable tolerability and the absence of drugs that have shown a greater benefit, it remains a second-line treatment option in HR-positive, HER2 negative (score 0) patients without BRCA mutation or visceral crisis and can be discuss with fulvestrant in second line after CDK4-6i. It is likely that within 5 years this treatment will be replaced in second line HR-positive breast cancer by new emerging treatments: drug-conjugated antibodies, tyrosine kinase inhibitors or immunotherapy in combination with chemotherapy.
  • ||||||||||  phenobarbital / Generic mfg., everolimus / Generic mfg.
    TWO CASES OF PREGNANCY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (ePoster (Virtual Only)) -  May 14, 2023 - Abstract #ERAEDTA2023ERA_EDTA_2249;    
    Female patients with TSC have increased risk of hemorrhagic complications of AMLs during pregnancy and it can be complicated by intrauterine growth restriction. A multidisciplinary approach is needed in the planning and monitoring pregnancies in these patients to achieve optimal outcomes.
  • ||||||||||  Real World Use of Systemic Therapy for Treatment of Advanced Thyroid Cancer (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_1664;    
    We identified patients with thyroid cancer who had prescription claims for at least one of the 15 SMKIs of interest (axitinib, cabozantinib, dabrafenib, entrectinib, everolimus, larotrectinib, lenvatinib, pazopanib, pralsetinib, selpercatinib, sorafenib, sunitinib, trametinib, vandetanib, and vemurafenib)...Since 2015 when lenvatinib was approved by the FDA for treatment of advanced differentiated thyroid cancer, it has become the most commonly prescribed SMKI for treatment of advanced thyroid cancer. However, variation exists in which SMKIs are used to treat patients with advanced thyroid cancer, with almost one-quarter of patients initiated on commercially available SMKIs.
  • ||||||||||  temozolomide / Generic mfg.
    Successful Treatment of Ectopic ACTH from Metastatic Gastrinoma with Temozolomide Monotherapy (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_276;    
    As hypercortisolism is associated with multiple risks including thromboembolic events, rapid reduction of cortisol biosynthesis was achieved with Ketoconazole...Temozolomide was very well tolerated; there were different reasons to hold Capecitabine including severe thrombocytopenia... Temozolomide should be considered in ACTH producing NETs refractory to conventional treatment strategies.
  • ||||||||||  Taltorvic (ridaforolimus) / Takeda, Merck (MSD), Torisel (temsirolimus) / Pfizer
    Journal:  The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches. (Pubmed Central) -  May 11, 2023   
    Since mTOR resistance mechanisms prevent the effects of mTOR inhibitors used in cancer treatments, new inhibition strategies should be developed. Inhibition approaches are created using nanoparticles, and one of them offers a promising treatment option with evidence supporting its effectiveness.
  • ||||||||||  Review, Journal:  BRD4: New Hope in the Battle Against Glioblastoma. (Pubmed Central) -  May 8, 2023   
    In addition, several BRD4 inhibitors have been evaluated for therapeutic purposes as monotherapy or in combination with chemotherapy, radiotherapy, and immune therapies. Here, we provide a critical appraisal of studies evaluating various BRD4 inhibitors and degraders as novel treatment strategies against GBM.
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Organoids as tools for functional precision oncology in advanced pancreatic cancer (POSTER HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_226;    
    P1
    We could identify in a clinically relevant turnaround time at least one putative hit on the chemogram in 90% of cases, and in 87% of cases hits were not SOC. These results warrant to be confirmed in a prospective randomized trial to address the efficacy of PDO-based functional precision oncology for the management of PDAC.